Targeted autophagic clearance of Tau protects against Alzheimer's disease through amelioration of Tau-mediated lysosomal stress.

IF 13.3 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Theranostics Pub Date : 2025-08-16 eCollection Date: 2025-01-01 DOI:10.7150/thno.118409
Bo Hyun Yoon, Jinho Kim, Sandip Sengupta, Chan-Jung Park, Minjoo Ko, Ji Hee Kang, Young Tag Ko, Yeji Kim, Seung Min Lim, Yoonhee Bae, MooYoung Choi, Yunyeong Jang, Ho Jeong Kwon, Hyo Jin Son, Hee Jin Kim, Taebo Sim, Keun-A Chang, Myung-Shik Lee
{"title":"Targeted autophagic clearance of Tau protects against Alzheimer's disease through amelioration of Tau-mediated lysosomal stress.","authors":"Bo Hyun Yoon, Jinho Kim, Sandip Sengupta, Chan-Jung Park, Minjoo Ko, Ji Hee Kang, Young Tag Ko, Yeji Kim, Seung Min Lim, Yoonhee Bae, MooYoung Choi, Yunyeong Jang, Ho Jeong Kwon, Hyo Jin Son, Hee Jin Kim, Taebo Sim, Keun-A Chang, Myung-Shik Lee","doi":"10.7150/thno.118409","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Lysosomal dysfunction could be an underlying cause of Alzheimer's disease, with Tau oligomer being an important inducer or amplifier of lysosomal stress associated with the disease. Tau oligomer is a well-known substrate of autophagy, and selective degradation of Tau with Tau-specific autophagy degrader might be feasible. <b>Methods:</b> Tau-specific autophagic degraders were synthesized by combining leucomethylene blue, linkers and a lysosomal degradation tag (Autac). Tau clearance and changes of Tau-mediated lysosomal stress by these degraders were studied <i>in vitro</i>. <i>In vivo</i> effects of a Tau-specific degrader were investigated employing a combined Tau/Aβ mutant mouse model characterized by an accelerated onset of neurological deficits. Human relevance was investigated using induced pluripotent stem cell (iPSC)-derived neuronal cells from an Alzheimer's disease patient. <b>Results</b>: Among Tau-specific Autac degraders, TauAutac-3 (TA-3) efficiently degraded Tau oligomer and monomer, an effect inhibited by bafilomycin A1, suggesting lysosomal Tau degradation. TA-3 treatment induced LC3, K63, OPTN or NDP52 puncta, which was partially colocalized with Tau oligomer. Signs of lysosomal stress, such as galectin-3 puncta, pHluorin fluorescence, altered lysosomal pH and CHMP2B recruitment, induced by Tau expression were reversed by TA-3. Autophagy impairment by Tau expression <i>in vitro</i>, likely due to lysosomal stress, was also reversed by TA-3. <i>In vivo</i>, TA-3 administration markedly reduced the accumulation of both Tau and Aβ in 6xTg mice, which was associated with amelioration of Tau-mediated lysosomal stress and autophagy impairment. Neuroinflammation characterized by increased numbers of GFAP<sup>+</sup> glial cells and Iba1<sup>+</sup> microglial cells, was also reduced following TA-3 administration. TA-3 remarkably improved neurologic deficits in 6xTg mice, such as impaired memory and reduced exploratory behavior. TA-3 reduced Tau and phospho-Tau accumulation in iPSC-derived neuronal cells from an Alzheimer's disease patient. <b>Conclusion:</b> These results suggest that Tau-specific autophagic (Autac) degraders could serve as novel therapeutic agents for Alzheimer's disease through reduction of Tau-mediated lysosomal stress.</p>","PeriodicalId":22932,"journal":{"name":"Theranostics","volume":"15 17","pages":"9240-9260"},"PeriodicalIF":13.3000,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439469/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Theranostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/thno.118409","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Lysosomal dysfunction could be an underlying cause of Alzheimer's disease, with Tau oligomer being an important inducer or amplifier of lysosomal stress associated with the disease. Tau oligomer is a well-known substrate of autophagy, and selective degradation of Tau with Tau-specific autophagy degrader might be feasible. Methods: Tau-specific autophagic degraders were synthesized by combining leucomethylene blue, linkers and a lysosomal degradation tag (Autac). Tau clearance and changes of Tau-mediated lysosomal stress by these degraders were studied in vitro. In vivo effects of a Tau-specific degrader were investigated employing a combined Tau/Aβ mutant mouse model characterized by an accelerated onset of neurological deficits. Human relevance was investigated using induced pluripotent stem cell (iPSC)-derived neuronal cells from an Alzheimer's disease patient. Results: Among Tau-specific Autac degraders, TauAutac-3 (TA-3) efficiently degraded Tau oligomer and monomer, an effect inhibited by bafilomycin A1, suggesting lysosomal Tau degradation. TA-3 treatment induced LC3, K63, OPTN or NDP52 puncta, which was partially colocalized with Tau oligomer. Signs of lysosomal stress, such as galectin-3 puncta, pHluorin fluorescence, altered lysosomal pH and CHMP2B recruitment, induced by Tau expression were reversed by TA-3. Autophagy impairment by Tau expression in vitro, likely due to lysosomal stress, was also reversed by TA-3. In vivo, TA-3 administration markedly reduced the accumulation of both Tau and Aβ in 6xTg mice, which was associated with amelioration of Tau-mediated lysosomal stress and autophagy impairment. Neuroinflammation characterized by increased numbers of GFAP+ glial cells and Iba1+ microglial cells, was also reduced following TA-3 administration. TA-3 remarkably improved neurologic deficits in 6xTg mice, such as impaired memory and reduced exploratory behavior. TA-3 reduced Tau and phospho-Tau accumulation in iPSC-derived neuronal cells from an Alzheimer's disease patient. Conclusion: These results suggest that Tau-specific autophagic (Autac) degraders could serve as novel therapeutic agents for Alzheimer's disease through reduction of Tau-mediated lysosomal stress.

靶向自噬清除Tau通过改善Tau介导的溶酶体应激来预防阿尔茨海默病。
背景:溶酶体功能障碍可能是阿尔茨海默病的潜在原因,Tau低聚物是与该疾病相关的溶酶体应激的重要诱导剂或放大器。Tau寡聚物是众所周知的自噬底物,使用Tau特异性自噬降解剂选择性降解Tau可能是可行的。方法:将白乙烯蓝、连接物和溶酶体降解标签(Autac)结合合成tau特异性自噬降解物。在体外研究了这些降解物对Tau的清除和Tau介导的溶酶体应激的变化。采用以神经功能缺陷加速发作为特征的Tau/ a β联合突变小鼠模型,研究了Tau特异性降解剂的体内效应。利用来自阿尔茨海默病患者的诱导多能干细胞(iPSC)衍生的神经细胞,研究了人类相关性。结果:在Tau特异性的Autac降解物中,TauAutac-3 (TA-3)能有效降解Tau寡聚物和单体,这一作用被巴菲霉素A1抑制,提示溶酶体降解Tau。TA-3处理诱导LC3、K63、OPTN或NDP52点与Tau低聚物部分共定位。TA-3可以逆转Tau表达诱导的溶酶体应激迹象,如半凝集素-3斑点、氟化素荧光、溶酶体pH改变和CHMP2B募集。体外自噬损伤的Tau表达,可能是由于溶酶体应激,也被TA-3逆转。在体内,TA-3可以显著降低6xTg小鼠中Tau和Aβ的积累,这与Tau介导的溶酶体应激和自噬损伤的改善有关。以GFAP+胶质细胞和Iba1+小胶质细胞数量增加为特征的神经炎症也在TA-3给药后减少。TA-3显著改善了6xTg小鼠的神经功能缺陷,如记忆受损和探索行为减少。TA-3减少了阿尔茨海默病患者ipsc来源的神经细胞中Tau和磷酸化Tau的积累。结论:这些结果表明,tau特异性自噬(Autac)降解物可能通过降低tau介导的溶酶体应激而成为治疗阿尔茨海默病的新药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Theranostics
Theranostics MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
25.40
自引率
1.60%
发文量
433
审稿时长
1 months
期刊介绍: Theranostics serves as a pivotal platform for the exchange of clinical and scientific insights within the diagnostic and therapeutic molecular and nanomedicine community, along with allied professions engaged in integrating molecular imaging and therapy. As a multidisciplinary journal, Theranostics showcases innovative research articles spanning fields such as in vitro diagnostics and prognostics, in vivo molecular imaging, molecular therapeutics, image-guided therapy, biosensor technology, nanobiosensors, bioelectronics, system biology, translational medicine, point-of-care applications, and personalized medicine. Encouraging a broad spectrum of biomedical research with potential theranostic applications, the journal rigorously peer-reviews primary research, alongside publishing reviews, news, and commentary that aim to bridge the gap between the laboratory, clinic, and biotechnology industries.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信